

5 September 2025

Our Ref: FOI 1340

Dear

**Freedom of Information Act 2000
Information in Relation to Asthma Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 8 August 2025.

A response to the questions you have raised has been provided by the Planning Performance and Informatics and Surgery, Elective Care, Maternity & Paediatrics Directorates and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Olivia Robinson
Information Governance Officer

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- **Benralizumab**
- **Dupilumab**
- **Omalizumab**
- **Reslizumab**
- **Mepolizumab**
- **Tezepelumab**

A1. Please see Table 1 below for the number of patients who have been treated for any condition in the last 4 months with the listed drugs.

Table 1

Drug	Number of Patients
Benralizumab	Nil
Dupilumab	137
Omalizumab	17
Reslizumab	Nil
Mepolizumab	Nil
Tezepelumab	Nil

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- **Age 6-11**
- **Age 12-17**
- **Age 18 and above**

Please see Table 2 below for a breakdown of the number of patients by age-groups treated in the last 4 months with any of the listed products.

Table 2

Drug	Age Group	Number of Patients
Dupilumab	6-11	2
Omalizumab	6-11	Nil
Dupilumab	12-17	9
Omalizumab	12-17	Nil
Dupilumab	18+	126
Omalizumab	18+	17

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

- **Dupilumab**
- **Omalizumab**

A3. Please see Table 3 for a breakdown of the number of patients that have been treated in the last 4 months by the Respiratory Medicine Department with the listed drugs.

Table 3

Drug	Number of Patients
Dupilumab	Nil
Omalizumab	Nil

Q4a. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year?

A4a. The Trust does not capture the diagnosis broken down by chronic sinusitis and nasal polyps, however, the Trust can advise that it is clinically coded as part of a patients diagnosis for an inpatient or day case stay.

Please see Table 4 for the most recent clinically coded 12-month period for the number of patients with the above referenced as part of their diagnosis.

Table 4

Coded Period	Number of Patients
1 November 2023 – 31 October 2024	<5

Please note where numbers in individual cells are 1-4, within Table 4, in line with Trust policy, it is given as <5, to reduce any risk of identification of individual patients.

Q4b. Of these patients, how many have been treated in the last 4 months with:

- **Benralizumab**
- **Dupilumab**
- **Omalizumab**
- **Reslizumab**
- **Mepolizumab**
- **Tezepelumab**

A4b. Please see Table 5 for a breakdown of the number of patients that have been treated in the last 4 months with the listed drugs.

Table 5

Drugs	Number of Patients
Benralizumab	Nil
Dupilumab	Nil
Omalizumab	Nil
Reslizumab	Nil
Mepolizumab	Nil
Tezepelumab	Nil